ImmunoPrecise Antibodies Ltd. - Asset Resilience Ratio
ImmunoPrecise Antibodies Ltd. (HYFT) has an Asset Resilience Ratio of 67.58% as of July 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read ImmunoPrecise Antibodies Ltd. (HYFT) financial obligations for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (1997–2020)
This chart shows how ImmunoPrecise Antibodies Ltd.'s Asset Resilience Ratio has changed over time. See what is ImmunoPrecise Antibodies Ltd.'s book value for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down ImmunoPrecise Antibodies Ltd.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see how much is ImmunoPrecise Antibodies Ltd. worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $27.54 Million | 67.58% |
| Total Liquid Assets | $27.54 Million | 67.58% |
Asset Resilience Insights
- Very High Liquidity: ImmunoPrecise Antibodies Ltd. maintains exceptional liquid asset reserves at 67.58% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
ImmunoPrecise Antibodies Ltd. Industry Peers by Asset Resilience Ratio
Compare ImmunoPrecise Antibodies Ltd.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO |
Biotechnology | 11.59% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 0.00% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS |
Biotechnology | 0.58% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
BrightGene Bio Medical Technology C
SHG:688166 |
Biotechnology | 1.00% |
|
BioArctic AB (publ)
ST:BIOA-B |
Biotechnology | 72.35% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for ImmunoPrecise Antibodies Ltd. (1997–2020)
The table below shows the annual Asset Resilience Ratio data for ImmunoPrecise Antibodies Ltd..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2020-04-30 | 0.00% | $104.00 | $27.26 Million | -15.51pp |
| 2016-04-30 | 15.51% | $214.14K | $1.38 Million | +15.22pp |
| 2010-04-30 | 0.30% | $16.20K | $5.47 Million | -0.17pp |
| 2009-04-30 | 0.47% | $32.50K | $6.93 Million | -4.44pp |
| 2008-04-30 | 4.91% | $253.25K | $5.16 Million | +3.85pp |
| 2007-04-30 | 1.06% | $58.75K | $5.56 Million | +0.83pp |
| 2006-04-30 | 0.22% | $9.00K | $4.05 Million | -0.59pp |
| 2001-04-30 | 0.81% | $9.40K | $1.16 Million | +0.24pp |
| 1999-04-30 | 0.57% | $9.40K | $1.66 Million | -6.17pp |
| 1998-04-30 | 6.73% | $197.32K | $2.93 Million | -50.56pp |
| 1997-04-30 | 57.30% | $2.22 Million | $3.88 Million | -- |
About ImmunoPrecise Antibodies Ltd.
MindWalk Holdings Corp. operates as a bio-native AI company. It focuses on the integration of artificial intelligence, multi-omics data, and advanced laboratory research to accelerate the discovery and development of biologics. The company, through its LensAI platform and HYFT technology, it partners with pharmaceutical and biotechnology companies to drive de-risk drug development and unlock ther… Read more